![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EMA Approves Four Applications for PRIME, Frowns on Another 14
EMA Approves Four Applications for PRIME, Frowns on Another 14
![EMA_Logo.gif](https://www.fdanews.com/ext/resources/test/Drug-Images3/EMA_Logo.gif?t=1579219264&width=430)
June 7, 2016
A European Medicines Agency committee has approved four applications for the PRIority MEdicines initiative, while rejecting another 14.
The candidates accepted by the Committee for Medicinal Products for Human Use include ChemoCentryx’s CCX168 for the treatment of active anti-neutrophil cytoplasmic antibody-associated vasculitis, Biogen’s aducanumab for the treatment of Alzheimer’s disease, Kite Pharma’s KTE-C19 for the treatment of diffuse large B-cell lymphoma and Novimmune’s NI-0501 for treatment of primary hemophagocytic lymphohistiocytosis.
PRIME was launched in March by the EMA as a way to accelerate breakthrough therapies through speedy engagement with sponsors with drug development advice to help companies strengthen clinical trial designs and improve patient selection.
Upcoming Events
-
21Oct